Cargando…
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
BACKGROUND: Immune thrombocytopenia (ITP) is characterized by primarily autoantibody-mediated platelet destruction and impaired platelet production resulting in thrombocytopenia and an increased risk of bleeding. Other manifestations include increased risk of thrombosis and diminished quality of lif...
Autores principales: | Kuter, David J., Bussel, James B., Ghanima, Waleed, Cooper, Nichola, Gernsheimer, Terry, Lambert, Michele P., Liebman, Howard A., Tarantino, Michael D., Lee, Michelle, Guo, Hailing, Daak, Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585997/ https://www.ncbi.nlm.nih.gov/pubmed/37869360 http://dx.doi.org/10.1177/20406207231205431 |
Ejemplares similares
-
P1604: IMPACT OF THROMBOPOIETIN LEVEL ON PLATELET RESPONSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TREATED WITH RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR
por: Kuter, David, et al.
Publicado: (2023) -
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
por: Boccia, Ralph, et al.
Publicado: (2020) -
Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia
por: Lee, Eun-Ju, et al.
Publicado: (2021) -
Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019) -
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)